Skip to main content

UPDATE 1-Regeneron profit edges past estimates

Feb 9 (Reuters) - Regeneron Pharmaceuticals Inc's adjusted profit edged past analysts' estimates helped by its flagship eye drug Eylea, even as lower-than-expected demand for its cholestrol-fighter Praluent hit revenue.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.